CA2650999A1 - Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases - Google Patents
Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases Download PDFInfo
- Publication number
- CA2650999A1 CA2650999A1 CA002650999A CA2650999A CA2650999A1 CA 2650999 A1 CA2650999 A1 CA 2650999A1 CA 002650999 A CA002650999 A CA 002650999A CA 2650999 A CA2650999 A CA 2650999A CA 2650999 A1 CA2650999 A1 CA 2650999A1
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- compound
- cancer
- alkyl
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68606205P | 2005-05-31 | 2005-05-31 | |
US60/686,062 | 2005-05-31 | ||
PCT/US2006/020986 WO2006130613A2 (en) | 2005-05-31 | 2006-05-30 | Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2650999A1 true CA2650999A1 (en) | 2006-12-07 |
Family
ID=37482228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002650999A Abandoned CA2650999A1 (en) | 2005-05-31 | 2006-05-30 | Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1896462A2 (zh) |
JP (1) | JP2008542382A (zh) |
CN (1) | CN101233129A (zh) |
AU (1) | AU2006252629A1 (zh) |
CA (1) | CA2650999A1 (zh) |
WO (1) | WO2006130613A2 (zh) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE035337T2 (en) | 2010-05-20 | 2018-05-02 | Array Biopharma Inc | Macrocyclic compounds as TRK kinase inhibitors |
WO2012052954A1 (en) * | 2010-10-20 | 2012-04-26 | Universite Bordeaux Segalen | Signatures of clinical outcome in gastro intestinal stromal tumors and method of treatment of gastroinstestinal stromal tumors |
EP3322706B1 (en) | 2015-07-16 | 2020-11-11 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
JP6888101B2 (ja) | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | RETキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピラジン化合物 |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
WO2019143991A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS |
CA3087972C (en) | 2018-01-18 | 2023-01-10 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
US11964988B2 (en) | 2018-09-10 | 2024-04-23 | Array Biopharma Inc. | Fused heterocyclic compounds as RET kinase inhibitors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU778723B2 (en) * | 1999-08-23 | 2004-12-16 | Kyorin Pharmaceutical Co. Ltd. | Substituted benzylthiazolidine-2,4-dione derivatives |
-
2006
- 2006-05-30 WO PCT/US2006/020986 patent/WO2006130613A2/en active Application Filing
- 2006-05-30 EP EP06771644A patent/EP1896462A2/en not_active Withdrawn
- 2006-05-30 AU AU2006252629A patent/AU2006252629A1/en not_active Abandoned
- 2006-05-30 JP JP2008514781A patent/JP2008542382A/ja not_active Withdrawn
- 2006-05-30 CA CA002650999A patent/CA2650999A1/en not_active Abandoned
- 2006-05-30 CN CNA2006800281850A patent/CN101233129A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1896462A2 (en) | 2008-03-12 |
WO2006130613A3 (en) | 2007-02-08 |
AU2006252629A1 (en) | 2006-12-07 |
WO2006130613A2 (en) | 2006-12-07 |
CN101233129A (zh) | 2008-07-30 |
JP2008542382A (ja) | 2008-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2650999A1 (en) | Substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases | |
JP5261575B2 (ja) | 化学化合物 | |
WO2013016720A2 (en) | Novel substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases | |
EP1605946B1 (en) | Thiazoles useful as inhibitors of protein kinases | |
AU2005230847B2 (en) | Anaplastic lymphoma kinase modulators and methods of use | |
US20040097566A1 (en) | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer | |
AU2013283318B2 (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and CNS disorders | |
TW202003505A (zh) | 甲基修飾酵素之調節劑、其組成物及用途 | |
AU2013230425B2 (en) | Substituted heterocyclic acetamides as kappa opioid receptor (kor) agonists | |
SK4772002A3 (en) | Tyrosine kinase inhibitors, pharmaceutical composition containing the same and their use | |
JP5463592B2 (ja) | アデノシンa1レセプターアンタゴニストとしての新規化合物 | |
BR112012000370B1 (pt) | Compostos úteis como medicamentos | |
JP3555620B2 (ja) | N−フェニル−アリールスルフォンアミド化合物、その化合物を有効成分として含有する薬剤、その化合物の合成中間体およびその製造方法 | |
RU2391342C2 (ru) | Новые азаиндолтиазолиноны в качестве противораковых агентов | |
US7897602B2 (en) | Indolinone compounds as kinase inhibitors | |
JP2008504324A (ja) | チアゾリノン非置換型キノリン | |
US20030216432A1 (en) | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | |
CN101039939B (zh) | 作为cdk1抑制剂的喹唑啉基亚甲基噻唑啉酮类 | |
JP2019523237A (ja) | 乳酸脱水素酵素の阻害剤としての1h−ピラゾール−1−イル−チアゾールおよびそれらの使用方法 | |
JP2008534646A (ja) | Cdk阻害剤としての置換1,5−ナフチリジンアゾリジノン | |
WO2006106721A1 (ja) | チロシンキナーゼ阻害作用を有するピリミジン誘導体 | |
US20050014767A1 (en) | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases | |
RU2758259C2 (ru) | Соединение формулы (I), фармацевтическая композиция, применение соединения формулы (I) для лечения гематологических и/или пролиферативных нарушений | |
RU2395509C2 (ru) | Тиазолинон-2-замещенные хинолины | |
EP2395001A1 (en) | Novel pyrimidine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |